Cargando…

Predictors of hepatic decompensation after TACE for hepatocellular carcinoma

AIM: To study predictive factors for hepatic decompensation after transarterial chemoembolisation (TACE) for hepatocellular carcinoma (HCC). METHODS: Between November 2009 and August 2010, of 254 patients with HCC who presented to our multidisciplinary HCC clinic for evaluation, 102 (40%) were amena...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohla, Mohamed A S, Abu Zeid, Mai I, Al-Warraky, Mohamed, Taha, Hossam, Gish, Robert G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599160/ https://www.ncbi.nlm.nih.gov/pubmed/26462282 http://dx.doi.org/10.1136/bmjgast-2015-000032

Ejemplares similares

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
por: Chen, Li, et al.
Publicado: (2021)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
por: Kim, Jung Hee, et al.
Publicado: (2017)

TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
por: Féray, Cyrille, et al.
Publicado: (2023)

Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC
por: Müller, Lukas, et al.
Publicado: (2022)

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Impact of preoperative TACE on incidences of microvascular invasion and long‐term post‐hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis
por: Yang, Yun, et al.
Publicado: (2021)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Transradial versus transfemoral arterial access in DEB-TACE for hepatocellular carcinoma
por: Ghosh, Abheek, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma
por: Cai, Yeyu, et al.
Publicado: (2018)

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE
por: Huang, Wu-Kui, et al.
Publicado: (2017)

Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma
por: Wang, Yujia, et al.
Publicado: (2022)

Bridging and downstaging with TACE in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant
por: Yin, Chao, et al.
Publicado: (2022)

Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma
por: Jiang, Jiang, et al.
Publicado: (2017)

TACE performed in patients with a single nodule of Hepatocellular Carcinoma
por: Terzi, Eleonora, et al.
Publicado: (2014)

RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma
por: Zhang, Jian, et al.
Publicado: (2014)

Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma
por: Wang, Jia-hong, et al.
Publicado: (2017)

TILA-TACE – an approach for effective local control of hepatocellular carcinoma
por: Chao, Ming, et al.
Publicado: (2019)

Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma
por: Kong, Lingxiang, et al.
Publicado: (2021)

Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
por: Zhang, Leida, et al.
Publicado: (2014)

Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma
por: Zhang, Ya-Qing, et al.
Publicado: (2017)

Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Liu, Shanshan, et al.
Publicado: (2023)

Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma
por: Hu, Hao, et al.
Publicado: (2016)

Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients
por: Chen, Chang-Zhi, et al.
Publicado: (2021)

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study
por: Wu, Jianbing, et al.
Publicado: (2017)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety
por: Li, Hui, et al.
Publicado: (2019)

Assessment of the feasibility of TACE combined with intratumoral injection of cisplatin in hepatocellular carcinoma
por: Zhaomin, Song, et al.
Publicado: (2015)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

Combination therapy: Meta-analysis of the effects of TACE and cryoablation on hepatocellular carcinoma
por: Yuan-Dong, Sun, et al.
Publicado: (2019)

Prognostic value of sarcopenic visceral obesity in hepatocellular carcinoma treated with TACE
por: Li, Yuxuan, et al.
Publicado: (2023)

Multidisciplinary Taiwan consensus for the use of conventional TACE in hepatocellular carcinoma treatment
por: Chang, Pi-Yi, et al.
Publicado: (2023)

Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2019)

Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
por: Scartozzi, Mario, et al.
Publicado: (2010)

Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE
por: Qu, Shuping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mrb27c11p965tot86nmf4f2u81